



BIODIEM LTD  
ABN 20 096 845 993  
Level 4,  
100 Albert Road,  
South Melbourne, Victoria, 3205  
Australia  
Phone: +613 9692 7240  
Web: www.biodiem.com

## Announcement

### EOFY 2021 Information

#### Highlights:

- **LAIV flu vaccine royalty receipt**
- **Progress in Opal's bid to secure lease to GSK Boronia manufacturing plant**
- **EOFY 2021 share price information**

**Melbourne, 22 September 2021:** Infectious disease therapy and vaccine development company BioDiem Ltd and its subsidiary company Opal Biosciences Ltd ("Opal") are pleased to provide the following update.

#### **Live attenuated flu virus (LAIV) vaccine licensee progress in China**

China-based Changchun BCHT Biotechnology Co (BCHT) holds an exclusive licence from BioDiem for the vaccine technology based on the live attenuated influenza virus (LAIV). BCHT's licence covers the private sector market in China for pandemic and seasonal influenza vaccines made using an egg-based production method.

BCHT holds a complementary licence to the LAIV for the public market in China via a sublicense from the World Health Organisation. In addition to annual milestone fees BioDiem recently received its first royalty payment from the sale of BCHT's influenza vaccine product in the China private sector market.

#### **Opal Biosciences Ltd ("Opal")**

Opal's strategic focus is now directed towards growing Australia's vaccine and pharmaceutical manufacturing capability. The lack of onshore manufacturing capability and risks of reliance on imported medicines has become evident during the current pandemic. In 2020 GSK announced it would close large pharmaceutical manufacturing plant in Boronia, Victoria, at the end of 2022. Opal has led the development of a plan to repurpose the Boronia site as a *Life Sciences and Biotechnology Development and Manufacturing Precinct*. Opal proposes to manufacture pharmaceutical products and vaccines on the site through a lease arrangement and has attracted other interested commercial and public parties for use of the site's extensive existing infrastructure. The infrastructure includes office spaces, laboratories and manufacturing and production facilities. There is also room for bespoke developments on vacant areas of the site. The life sciences precinct's aim would be to facilitate collaboration between researchers and industry partners and provide pharmaceutical development support and manufacturing facilities.

In light of this significant new activity Opal withdrew its capital raising to acquire Formulytica in July and all applicant monies were returned in full to applicants. Opal has recently concluded a placement raising \$250,000 to assist progress for the planned activity for the precinct. The placement was priced at \$0.075 (7.5 cents) per share and each share had a free attaching option exercisable at \$0.075 (7.5 cents) each, expiring 12 months from the issue date.

#### **EOFY Share Price information**

The EOFY 2021 share price information is as follows, being the last sale price:

- BioDiem ordinary shares = \$0.08 (8 cents)
- BioDiem preference shares = \$0.08 (8 cents)

For those BioDiem shareholders who also separately hold shares in Opal, the EOFY 2021 share price of Opal Biosciences ordinary shares was \$0.25 (25 cents).

**Shareholder Information at Share Registry, Computershare.**

Shareholders are asked to ensure their contact details/email addresses are up-to-date at Computershare. This can be done online via the Computershare Investor Centre ([www.computershare.com.au](http://www.computershare.com.au)).

- ENDS -

**About BioDiem Ltd**

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply.

Biodiem has two commercial licences:

- Changchun BCHO Biotechnology Co (China) launched Defluvac™ in China in August 2020; and
- Serum Institute of India's Nasovac-S™ is marketed in India.

For additional information, please visit [www.biodiem.com](http://www.biodiem.com).

**About Opal Biosciences Ltd**

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. Opal is currently seeking to diversify its focus by considering commercial opportunities within the Australian biotechnology and pharmaceutical industry. Opal's strategic focus is now directed towards growing Australia's vaccine and pharmaceutical manufacturing capability which has become evident as a sovereign need during the recent pandemic

For more information, please visit [www.opalbiosciences.com](http://www.opalbiosciences.com).

**Further information**

Julie Phillips, Chief Executive Officer, BioDiem Ltd

Phone +61 3 9692 7222

Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)

Twitter @biodiem @opalbiosciences